Back to search results

Alpha-1 Blockade for Alcohol Use Disorder (AUD)

This study is testing if a drug called doxazosin can help people with Alcohol Use Disorder (AUD) reduce their drinking. Doxazosin is compared to a placebo (an inactive substance that looks like the drug). You might be able to join if you are 18 or older, have AUD, want to drink less or stop, and are in good health. To see if the treatment works, researchers will measure how much alcohol participants drink after 6 weeks. The study's current status is unclear.

Study design
This is a double-blind, randomized clinical trial with 184 participants, meaning neither you nor the study staff will know if you are receiving doxazosin or placebo. It is a 16-week study comparing doxazosin to a placebo.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The main goal is to measure alcohol consumption at 6 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04135846

Alpha-1 Blockade for Alcohol Use Disorder (AUD)

Recruiting
PHASE2Ages 18+InterventionalTreatment
Brown University
~184 participants
Updated 2026-03-20 on ClinicalTrials.gov
What's tested:DoxazosinPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Alcohol consumption
Measured over 6 weeks

Conditions

Alcohol Use Disorder (AUD)

Explore related trials

Alcohol use disorder

Where it's being run

1 sites across 1 states
Rhode Island1

Study leadership

  • Carolina L Haass-Koffler, PHARMD, PHD · PRINCIPAL_INVESTIGATOR · Brown University

Who to contact

Zoe L Brown, BA
[email protected]
401-863-6646
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or female, 18 years of age
Meet the DSM-5 criteria for AUD
Desire to reduce or quit alcohol drinking
Breath alcohol (BrAC) = 0.00 at each visit
In good health as confirmed by medical history, physical examination and lab tests
Willing to adhere to the study procedures
Understand informed consent and questionnaires in English at an 8th grade level

Exclusion

Women who are breastfeeding or /positive urine test for pregnancy
CrCl\<60mL/min
Suicide attempt in the last three months
Current diagnosis of other substance disorder other than nicotine as assessed by self-report and urine toxicology screen at baseline
Current use of medication that may interact with doxazosin and/or yohimbine
History of allergy to any alpha receptor blockers
Clinical Institute Withdrawal Assessment for Alcohol revised (CIWA-Ar) score ≥ 8
Treatment with disulfiram, naltrexone, acamprosate, topiramate within 1 month prior to screening
Treatment with any alpha-blocker
Individuals with cardiac heat failure (CHF), as assessed by the medical history, the physical exam and the ECG.
Baseline hypotension defined as BP reading lower than 90/60 mmHg
Use of phosphodiesterase inhibitors (PDE5) erectile dysfunction medication

What this trial measures

  • Alcohol consumption6 weeks

    Number of drinks per week (DPW) in naturalistic condition as measured by the timeline follow-back (TLFB)